Jazz Pharmaceuticals plc
JAZZ · Nasdaq · United States · Health Care · Pharma / Biotech / Life Sci
- Coverage
- FY2016–FY2025
- History
- 10 years
- Latest filing
- 10-K · SEC EDGAR
- Reporting
- USD
- Fiscal year end
- December
- Last updated
- Feb 2026
Headline figures
Jazz Pharmaceuticals plc at a glance
In FY2025, Jazz Pharmaceuticals plc reported revenue of USD 4,268 mn, EBITDA of USD 1,717 mn, EBITDA margin of 40.2%.
| USD mn | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 4,069 | 4,268 | |||
| EBITDA | 1,832 | 1,717 | |||
| EBITDA margin | 45.0% | 40.2% | |||
| Free cash flow | 1,358 | 1,297 | |||
| ROIC | 20.9% | 9.5% |
The full 10-year history, every line item and each formula are in the platform.
In the platform
- Stat Book — normalized and as-reported IS, BS and CF
- Up to 10 years of annual and quarterly history
- Peer benchmarking and the stock screener
- Corporate risk scorecard
- DCF model from the filed inputs
- Tearsheet and live Excel formulas